The hallmarks of cancer
Neoplastic diseases are highly complex and heterogeneous. However, these diseases have shared common traits. Douglas Hanahan and Robert Weinberg published in 2000 "The hallmarks of cancer", a report of principles that rationalise the complexity displayed by malignancies [8] . Six distinctive and complementary hallmarks that eventually favour tumour growth and metastatic dissemination have been proposed at this time and updated 10 years after [9] . They are briefly explained here ( Figure 2 ). The accumulation of mutations due to genomic instability favours the appearance of the following hallmarks:
i. Sustained proliferative signalling. Cancer cells have the ability to maintain constant proliferation. In contrast, normal cells control their proliferation which confers on them the maintenance of homeostasis and tissue architecture. Cancer cells reprogram the release of growth factors and the expression of their associated receptors in order to increase their proliferation rate. Every pathway that controls positively or negatively the mitogenic activity is a target of choice for carcinogenesis-inducing mutations. Cancer cells may even also reprogram and induce neighbouring normal cells to emit growth factors [10] .
ii. Evasion from growth suppressors. Sustained constant proliferation occurs through the first-mentioned hallmark but cannot be completed unless the negative regulators of proliferation are neutralised. Some proteins, the so-called tumour suppressors, are responsible to sense and further decide if the cell should undergo division, senescence, or apoptosis. Rb (retinoblastoma protein) [11] and p53 (commonly called the "guardian of the genome") [12] are such proteins and are unsurprisingly common targets of inactivating mutations.
iii. Resistance to cell death. Normal cells that undergo replication failure or those that encounter excessive stress normally undergo a form of cell suicide called apoptosis. The regulation of apoptosis is finely tuned at physiological levels, in particular by showing an equilibrated balance between anti-and pro-apoptotic protein activities [13] . Apoptosis can be triggered by extrinsic factors (for example by engagement of the Fas receptor) or from within the cell (intrinsic mitochondrial cascade), typically after DNA damage. Both situations lead to the eventual activation of the proteases called caspases, which cleave various proteins essential for cell homeostasis maintenance, and therefore leads to progressive cell disassembly. Genomic instability allows the cancer cells to generate an unbalanced anti-apoptotic signature by activating antiapoptotic signalling and repressing the pro-apoptotic ones [13] . The diversity of strategies that cancer cells use to counteract apoptosis reflects the multiplicity of signalling leading to cell death. Other characterised kinds of cell death like autophagy [14] and necrosis [15] are also bypassed by cancer cells.
iv. Enabled replicative immortality. Normal cells are only able to pass through a limited number of division cycles, after which they enter into a viable but non-replicative senescence phase. They alternatively enter in a phase called crisis and die by apoptosis. This fate is mainly attributed to the telomere (chromosome extremities) shortening [16] . Telomeres of dividing cells shorten at every cell cycle, which is thought to eradicate their protective effect on chromosomal ends. The telomerase is a specialised DNA polymerase that adds DNA segments to the telomeres. In normal cells, telomerase is almost always absent, while more than 90% of the reported immortalised cells display high levels of telomerase [16] . Acquisition of the enhanced telomerase activity confers a strategy for unlimited replication of cancer cells.
v. Induction of angiogenesis. The fast growth and division of cancer cells necessitates constant support in nutrients and oxygen. These latter are supplied by the blood. The generation of new vessels is called angiogenesis and is a physiological process during embryogenesis and female reproductive cycling. It is however mainly switched off at adult stages and physiological conditions. To alleviate the tumour needs of nutrients and oxygen, tumour cells have evolved strategies to create their own vasculature [17] . The angiogenic switch triggered by cancer cells is heterogeneous but almost always results in production of a released factor called vascular growth factor-A (VEGF) that prompts endothelial cells to from a neovasculature [18] .
vi. Activated invasion and metastasis. The ability of cancer cells to disseminate through the body is undoubtedly their most harmful property, which almost always leads to death. It is also the least understood hallmark of all. In addition to providing the nutrients and oxygen, the newly created vessels offer to cancer cells the possibility to disseminate across the body. Only a few cancer cells will have the ability to complete the long metastatic journey. Succeeding in initiating metastasis involves several critical steps discussed in detail below.
vii. Other biological processes. In addition to the six hallmarks set out in this section, studies conducted over the last decades identified other biological processes as emerging hallmarks of cancer. Among those is the ability of cancer cells to escape from immune surveillance and the reprogramming of energy metabolism, a process that is also called the "Warburg effect". In addition to the fact that the cancer cells can escape from immune surveillance, recent data indicate that immune cells could also provide growth, survival, and proangiogenic factors to the tumour cells (reviewed in [19] ). To fuel their increasing need of energy, the cancer cells are prone to reprogram their energy metabolism by opting for an aerobic glycolytic metabolism, which is a mechanism allowing to produce lactate starting from glucose in presence of oxygen [20] . This glycolytic switch acidifies the tumour microenvironment which results in several selective advantages for the cancer cells (reviewed in [20] ). Another important observation is the increasing consideration for the protective role of the stroma associated with cancer cells.
Molecular basis of the metastatic cascade
The metastatic cascade is highly complex and involves sequential multistep processes [21] ; the consequence of this is that only a few pre-metastatic cells will survive until the end of the process to eventually form metastases [22] . There are still debates on which mode is utilised by the cell to form a metastasis [23] . The linear progression model states that all the mutations that are necessary to disseminate are acquired within the primary tumour while the parallel progression model favours the hypothesis that mutations are acquired sequentially in a spatial manner, and therefore that cells which leave the primary tumour are not fully metastatic [24] . Regardless of the dissemination mode, metastatic cells should be able to undergo a physiological process called epithelial-mesenchymal transition (EMT). EMT is a reversible reprogramming allowing epithelial cells to dedifferentiate and acquire de-adhesive and pro-migratory properties [25] . Concretely, pre-metastatic cells have first to detach from the primary tumour mass (Figure 3 ). This phenomenon is now widely accepted to be a consequence of the loss of the E-cadherin adhesion receptors that mediate cell-to-cell interactions [26] . Modulation of the interaction with the extracellular environment is also a crucial event and is mainly achieved by activating or repressing a set of adhesion receptors called integrins. The activation of proteases such as the matrix metalloproteinases (MMPs) permits cancer cells to find a path through the extracellular matrix (ECM), which is a network of proteoglycans, polysaccharides, and fibers mainly constituted by collagen, fibronectin, laminin, and vitronectin [27] . This is however not sufficient for the invasion process. In order to weave a path, the cells must increase their motility machinery by modulating the cytoskeleton (discussed in detail below). Once the pre-metastatic cell has reached the lymphatic or hematogenous systems, it has to cross the endothelial barrier, a process called intravasation [28] . The dissemination is then driven by the flow of the lymph or blood, but cells that are not able to survive in an anchorage-independent fashion will die at this step. Additionally, surviving cells should escape from the immune system surveillance. The succeeding ones are then helped by platelets and leukocytes to attach to the vessels in a selectindependent manner and will then cross the endothelial barrier back, a process called extravasation [28] . Finally, cells have to invade the distant organ parenchyma, which is often different from the primary tumour microenvironment in terms of ECM components [28] . At this moment, the metastatic cells reverse the mesenchymal phenotype in order to acquire a proliferative and structured state back; this program is called mesenchymal-epithelial transition (MET) and allows the cells to colonise and form micrometastasis and then eventually macrometastases [29] .
Despite the impressive obstacle-associated journey to form a metastasis, the metastatic cell proteome only slightly differs from the primary tumour cell as exemplified in the breast-to-bone malignant dissemination [30] . Overexpressed proteins involved in this breast-to-bone dissemination signature are proteins involved in bone-specific functions like bone homing and degradation, but also proteins involved in more general aspects of dissemination like angiogenesis (FGF5 and CTGF), extracellular matrix degradation (MMP-1 and proteoglycan-1). Metastatic markers that target the motility machinery were also found; for example RhoC (Ras homologous C), a small GTPase involved in actin cytoskeleton remodelling [31] .
Any failure to complete one single step of the metastatic cascade would lead to the arrest of the entire process. This therefore raises hope for finding drugs that prevent the metastatic cascade by targeting isolated and specific features of metastatic cells.
Generally used therapies for cancer

Therapy against cancer and metastasis
Genomic instability makes cancer a moving target. The most commonly used treatment against cancer remains surgery when applicable, in addition to radiotherapy and systemic therapies including chemo-, immune-, and hormonal therapy. Surgery aims to physically remove the tumour mass; it is however not feasible in every organ as well as in many invasive cancer, the shape of which is not well delimitated. Radiotherapy uses ionizing radiation to kill malignant cells. Ionizing radiation induces DNA simple and double strand breaks that lead the cell to undergo apoptosis or mitotic catastrophe. Fifty percent of the cancer-diagnosed patients are treated with radiotherapy with possible adjuvants of anticancer drugs.
Chemotherapies are organised in several groups:
1. The alkylating agents that cause DNA cross-linking and strand break, leading to replicative failure and apoptosis.
2. The antimetabolites are analogues of nucleic acids that inhibit enzymes involved in DNA synthesis.
3. The alkaloids that bind and disrupt the microtubule cytoskeleton, this latter being crucial for the mitotic spindle and therefore for the cell cycle.
4. The antibiotics that also cross-link the DNA.
5. The inhibitors of topoisomerase, an enzyme required during DNA replication.
Immunotherapy generally aims to target or treat tumours with immuno-enhancers. These latter prompt the immune system to attack the tumour cells. Hormonal therapy is also suited for treating certain cancers that strictly depend on the presence of a hormone. In this case, the therapy aims to block the hormone-induced signalling.
Side-effects and resistance to most of these therapies remain however a major concern. The genomic instability favours heterogeneity and therefore the possibility to render a few cells resistant to the drug used, which is the main issue in cancer therapy. Nowadays, plenty of small molecule inhibitors have come out and appear promising as well as target more specifically some hallmarks of cancer ( Figure 4 ). An attractive strategy to reduce resistance to therapy is to prevent cells from having the possibility to use an "emergency exit" by creating a cocktail of drugs that target different hallmarks of the cancer cells (Figure 4 ). The emergence of personalised therapy will help to define the Achilles heel of each tumour and therefore to use the appropriate cocktail of drugs. As mentioned earlier, patients die from metastases. Unfortunately, only a few drugs target the metastatic cascade per se [32] . The others are rather hampering the proliferation of pre-established metastases. An illustration of this is the B-Raf inhibitors for malignant melanoma treatment. B-Raf, an effector of Ras, was often found mutated and thereby constitutively activated in malignant melanoma [33] . B-Raf inhibitors development substantially helped in treating these cancers, they however target the proliferating capacity of the metastasis and not their dissemination capacities. Drugs that are used to counteract the metastatic cascade are mainly anti-angiogenic agents, inhibitors of matrix metalloproteinases (MMPs) and those that target the tumour microenvironment of the secondary site [34] . An anti-angiogenic agent such as Bevacizumab, a monoclonal antibody directed against VEGF, is now used for treating metastatic colorectal cancer. Such drugs prevent vessel development and have the double effect of depriving the cells of nutrients and of a transport mean. An example of targeting the secondary site microenvironment is provided by Denosumab, an antibody targeted against RANKL (receptor activator of nuclear factor kappa-B (NF-κB) ligand). The release of RANKL leads to bone resorption, which is a facilitating event during bone invasion. Neutralizing RANKL with Denosumab is used against osteoporosis and for bone metastasis prevention. The invasion process is also the subject of intense therapeutic development. Melanomas and glioblastomas are currently treated with inhibitors of α V -integrin, an adhesion protein involved in cell-ECM interaction. α V -integrin inhibitors comprise neutralising antibodies (such as etaracizumab) or cyclic peptides derived from the RGD tripeptide integrin ligand (such as cilengitide). Anti-MMPs were also developed and are currently under clinical trials. They prevent invading cells from digesting the extracellular matrix. A novel class of inhibitors, the inhibitors of c-MET, a tyrosine kinase that controls drug resistance, stemness, invasion, and angiogenesis, seem promising as they simultaneously target several cancer hallmarks at the same time. Despite all that, cancer therapy still lacks effective anti-metastasis drugs.
Biocomplexes in cancer therapy
Photodynamic therapy (PDT)
Newly emerged therapies of cancer include the combination of multiple facets of approaches; one of the promising applications is photodynamic therapy (PDT). This type of therapy has emerged as an alternative approach to chemotherapy and radiotherapy for cancer treatment. Such therapy is based on a photosensitizer (PS), which is perhaps the most critical component of PDT, and this newly introduced therapy is a continuously interesting area of intense scientific research. Classically, the photosensitizer's traditional use was achieved by molecules like porphyrins, which have dominated the field of photosensitizer therapy ( Figure 5 ). However, photosensitizer agents, major disadvantages are low water solubility, poor light absorption, and reduced selectivity for targets. In order to overcome these disadvantages, experts in the field have introduced polysilsesquioxane (PSilQ) nanoparticles that are crosslinked homopolymers formed by the condensation of functionalised trialkoxysilanes or bis(trialkoxysilanes). PSilQ particles provide an interesting platform for developing PS nanocarriers. Tackling the major problems of introducing the therapeutic components, the PSilQ nanoparticles provide the reliability to carry a large payload of PS molecules; their surface and composition can be tailored to be more target-specific based on the load. In addition to their small size, nanoparticles can penetrate deep into tissues and be readily internalised by cells. The authors describe the PSilQ nanoparticles with a high payload of photosensitizers that were synthesised, characterised, and applied in vitro. The network of this nanomaterial is formed by "protoporphyrin IX (PpIX) molecules chemically connected via a redox-responsive linker". Under reducing environment such as the one found in cancer cells, the nanoparticles can be degraded to efficiently release single photosensitizers in the cytoplasm. In fact, recent advances have shown that the phototoxicity of this porphyrin-based PSilQ nanomaterial was successfully demonstrated in vitro using human cervical (HeLa) cancer cells. Future research will build on this finding in order to improve the platform so that the nanoparticles hopefully can be further functionalised with other components including for example polyethylene glycol (PEG) and target-specific ligands to improve its biocompatibility and target specificity. 
Metal complexes as platforms for cancer therapy
Metals are essential cellular components that play a major role in the function of several indispensable biochemical processes for living organisms, mainly being enzymes cofactors. Metals are endowed with unique characteristics that include redox activity, variable coordination modes, and reactivity towards organic substrates. Metals are tightly regulated under normal conditions due to their high reactivity, and therefore aberrant metal ion concentrations are associated with various pathological disorders, including cancer. For the above-mentioned reasons, coordination complexes, either as drugs or prodrugs, become very attractive probes as potential anticancer agents. After the discovery of cisplatin, cis-[PtII(NH 3 ) 2 Cl 2 ], which led to the interest in platinum(II) and other metal-containing complexes as potential novel anticancer drugs. However the interests in this field are concerned with uptake, toxicity, and resistance to metallodrugs.
Platinum-based cancer therapy: a start of a new phase
Platinum-based compounds anticancer therapy is based on ligand exchange kinetics. For example, a platinumligand bond exhibits similar thermodynamic durability (less than 100 kJ/mol), which is actually much weaker than typical coordination bonds, such as C-C, C-N, or C-O single and double bonds (between 250 and 500 kJ/mol). The ligand exchange behaviour is rather slow. Such a slow exchange behaviour gives a high kinetic stability and allows much slower ligand exchange reactions, rendering the reaction period rather longer on the order of minutes to days. Additionally, in the case of Pt(II) compounds, ligands are mainly oriented in the trans position and are more rapidly substituted than those in the cis-position. The next chapter of this book is focused on the platinum-based drugs.
Zinc in cancer therapy
Zinc is a cofactor of many cellular enzymes and another indispensable trace element that plays a critical role in a wide range of cellular processes including cell proliferation, differentiation, and defense against free radicals. Zinc acts as a key structural component in many proteins and enzymes, including transcription factors, and cellular signaling proteins. The effects of the well-defined complexes of pyrrolidine diothiocarbamate complexes containing zinc, Zn(PyDTC) 2 , and copper, Cu(PyDTC) 2 , were investigated as potential proteasome inhibitors. Interestingly, these complexes were found to specifically target and inhibit the chymotrypsin-like activity of cellular 26S. In additon this effect does not seem to be specific to zinc only since the authors demonstrated that both Cu(EtDTC) 2 and Zn(EtDTC) 2 displayed a much higher potency to inhibiting the 26S proteasome in intact breast cancer cells. Another target metal that is being foreseen in cancer therapy is copper, which is enriched in various human cancer tissues and is an essential cofactor for tumour angiogenesis processes. Under normal biological conditions, copper exists in both (Cu + ) and (Cu 2+ ), and it serves as a cofactor in redox reactions, such as the mitochondrial electron transport chain. Copper was found to be a critical angiogenic effector by stimulating the proliferation and migration of endothelial cells. Therefore copper could be implicated in antitumour development, by an anti-angiogenic therapy using copper chelators. Compounds such as diethyldithiocarbamate (DDTC) and pyrrolidine dithiocarbamate (PDTC) were capable of binding copper and able to form complexes that potently inhibit the proteasomal chymotrypsin-like activity that suppresses proliferation and induces apoptotic cell death in cultured human prostate cancer cells [35] .
Copper in cancer therapy
It is known that copper plays a role in the growth and progression of malignancy has been the subject of intense investigation. It was found that copper levels are altered in tumours in mice and humans; in addition, copper is found in serum and tissue found in various human tumours including breast, prostate, colon, lung, and brain. Disulfiram (tetraethylthiuram disulfide, DSF) is a clinically employed drug that when mixed with CuCl 2 undergoes a dramatic colour change, which indicates that a chemical reaction between DSF and copper has occurred. Therefore employing the biology of a tumour where higher levels of copper compared to normal tissue are found, very innovative strategies are being developed of targeting elevated copper levels with DSF, and the authors of this work hypothesised that the resultant DSF-copper complex could possess potent tumourspecific killing activity by selectively inhibiting the proteasome in tumour cells [35] .
Peptide therapeutics
The field of peptide therapeutics has grown rapidly in recent years. In 2012, the number of peptides that reached market approval and clinical trials has never been higher [36] . Twelve peptides were approved in 2012 compared to~1.3 per year in the beginning of the 2000s. Virtually all biological fields are concerned by peptide development, with oncology and metabolism domains being at the forefront of this research.
Peptides have suffered a lot from their low biodelivery, bioavailability, and short half-lives [37, 38] . In addition, they are often rapidly cleared from the circulation by hepatic and renal routes. Still there are solutions to overcome these limitations. The proteolytic cleavage of peptides can be significantly improved first by replacing the oral administration by in situ injections, which already prevent the negative effects of gastrointestinal proteases. Second, the usage of unnatural amino acids (D-configuration), peptide cyclisation or the replacement of peptide bonds by isosteric bonds alo prevents proteases from cleaving these peptides in [37] . The short half-life of peptides is not always a bad aspect as compared to small molecules that stably toxically accumulate within organs, the peptide accumulation is often only transient and thus doses can be more easily controlled. The short size of peptides gives them the potential to penetrate the cells better than recombinant proteins or antibodies. In addition, coupling these peptides to cell-penetration peptides (CPPs) and organ targeting sequences further improves their delivery and specificity. More generally, it is widely accepted that peptides display more specificity towards their targets as they are often mimicking natural proteins, which in addition limits the side-effects associated to non-specific targets [39] .
In cancer therapy, peptide efficacy was approved particularly due to their efficient induction of apoptosis or antagonizing integrins for example. This field is currently extensively studied and much more remains to be discovered.
Peptides in cancer therapy
Until recently most research efforts aimed at developing anti-cancer tools were mainly concentrated on small molecules and their biology. The current usage of smaller compounds and alternative compounds are now being increasingly assessed for their potential anti-cancer properties, including peptides and peptide-derivatives. The previous limitation of peptide usage was the fact that they do not optimally cross cell membranes. This point was alleviated with the characterisation of cell-permeable sequences. Most anti-cancer peptidic compounds induce apoptosis of tumour cells. This is achieved by modulating various pathways that might shift the balance between anti-apoptotic and pro-apoptotic proteins. The biology of these modulating peptides is principally based on altering the activity of Bcl-2 family members that control the release of death factors from the house of power in the cells (the mitochondria) or by inhibiting negative regulators of caspases, the proteases that mediate the execution of protein cleavage and mainly induce the apoptotic response in cells besides other newly discovered non apoptotic functions. In parallel, the shift in the pro-and anti-apoptotic balance could be achieved by inhibiting the inhibitors. Researchers have identified Smac inhibitors that target the inhibitors of apoptosis proteins (IAPs), the family known to inhibit caspases and therefore induces cell death and ultimately vanishes the cancer colony. Similarly, a tumour suppressor and oncogenic sensor called p53 inhibits cell cycle for repair or induces apoptosis. The p53 protein counteracts cancer development by its apoptosis-inducing capacity. Unsurprisingly, p53 and p53 regulators are often mutated in many human cancers, and one of the major goals in cancer therapy is to identify a way to allow the restoration of a functional p53 apoptosis signaling response in cancer cells. For example, a 15 amino acid long peptide derived from a domain of p53 was shown to negatively regulate its own transcriptional activity, and it was shown that this peptide can activate latent forms of p53 when injected into cells, therefore reverting many of the inactivated p53 mutant back into activation phase. This finding shows the promising facet of peptides as re-activation of the p53 pathway would lead to tight control in the cell cycle again and therefore a rapid control on cancerous cells. Pro-apoptotic anti-tumour peptides will soon be tested for their efficacy in patients with cancers. There is a long list of pro-apoptotic peptides (Table 1) [40] . Most of these peptides were tested and verified in animal models. Some of these peptides have been shown to inhibit the growth of tumours in mouse models. 
TAT-RasGAP 317-326 as a dual sensitizer and anti-metastatic tool
TAT-RasGAP 317-326 is a cell-permeable peptide that contains a ten amino acid sequence derived from the p120 GTPase-activating protein (RasGAP). This peptide has been shown to increase the sensitivity of tumour cells specifically toward several anticancer treatments both in vitro and in vivo. Indeed, chemotherapeutic agents such as cisplatin, doxorubicin, adriamycin, etc. have been shown to be more efficient in the presence of TATRasGAP 317-326 . Moreover, this sensitising effect was also observed using radiotherapy and photodynamic therapy. Importantly, this peptide alone does not induce apoptosis [41] [42] [43] [44] . The RasGAP-derived peptide was also shown to be an inhibitor of cell migration and invasion [45] . Furthermore, among the ten amino acids from Ras-GAP, only two tryptophan residues were shown to be crucial for both sensitisation to apoptosis and inhibition of cell migration properties, making the W×W motif a potential candidate for anticancer drug design [46] .
Conclusions
There is no doubt about the critical role that metals play in the functioning and maintenance of life, highlighted by playing major roles of cofactors of enzymes in biological reactions. The clinical success of cancer treatment would be made much more efficient by the merging of one or more of the anti-cancer treatments we discussed in this chapter. The great success of cisplatin provided a proof that for investigating metals, and their role in defined biological processes might be essential in addition to their coordination in complexes as potential anticancer agents. Design strategies of novel platinum for example has led to the finding of different generations of the compound that is still being under intense investigation to address shortcomings of previous generation of platinum compounds. These findings, including what has been reported mainly by targeting the ubiquitin-proteasome pathway with metal based compounds (copper-, zinc-and gold-containing complexes), is an emerging concept in developmental therapeutics and would represent a significant progress in the developing novel anticancer drugs.
Although bio-complexes are not leading the pharmaceutical market in contrast to small molecules, this chapter has highlighted that they remain very attractive. Metals display potent anti-cancer activities, and their costs is very low. Anticancer peptides, on the contrary, might be more cost-effective but generally display more specificities towards their biological target, which is not negligible when a major current goal is to decrease drug side effects. Nevertheless, their development remains very slow. One active field of research is the translation of these bio-complexes into small molecules bearing the same activities and being more attractive in terms of industrial development. Smac mimetics represent a good example of this trend since several clinical trials are now ongoing.
